A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
|
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [11] Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia
    Obradovic, M.
    Mrhar, A.
    Kos, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (12) : 1979 - 1988
  • [12] Cost-effectiveness analysis of paliperidone palmitate compared to other antipsychotics indicated for the treatment of schizophrenia in France
    Druais, S.
    Doutriaux, A.
    Cognet, M.
    Lancon, C.
    Samalin, L.
    Levy, P.
    Godet, A.
    Guillon, P.
    EUROPEAN PSYCHIATRY, 2014, 29 (08) : 653 - 653
  • [13] Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK
    Davies, Andrew
    Vardeva, Kawitha
    Loze, Jean-Yves
    L'Italien, Gilbert J.
    Sennfalt, Karin
    van Baardewijk, Marc
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3275 - 3285
  • [14] Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia - Response
    Kos, M.
    Mrhar, A.
    Obradovic, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (07) : 1120 - +
  • [15] Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial
    Rosenheck, RA
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S32 - S32
  • [16] Comments on 'Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia'
    Koh, S. S.
    Meyer, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (07) : 1120 - 1120
  • [17] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS OTHER ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA IN FRANCE
    Doutriaux, A.
    Cognet, M.
    Druais, S.
    Lancon, C.
    Samalin, L.
    Levy, P.
    Godet, A.
    Guillon, P.
    VALUE IN HEALTH, 2014, 17 (07) : A459 - A459
  • [18] COST-EFFECTIVENESS OF SERTINDOLE AMONG ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA IN SOUTH KOREA
    Kim, B. R. M.
    Lee, H. J.
    Park, B. H.
    Yang, B. M.
    Lee, T. J.
    VALUE IN HEALTH, 2010, 13 (07) : A554 - A554
  • [19] COST-EFFECTIVENESS OF ANTIPSYCHOTICS FOR THE TREATMENT OF RELAPSE PREVENTION FOR SCHIZOPHRENIA. THE SPANISH PERSPECTIVE
    Garcia-Agua Soler, N.
    Garcia-Ruiz, A. J.
    Martos-Crespo, F.
    Perez-Costillas, L.
    Alcalde de Hoyos, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 70 - 70
  • [20] Cost-effectiveness of Paliperidone Palmitate Versus other Antipsychotics for the Treatment of Schizophrenia in France
    Doutriaux, A.
    Druais, S.
    Cognet, M.
    Lancon, C.
    Samalin, L.
    Levy, P.
    Godet, A.
    Guillon, P.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S11 - S12
12345